The care of persons with recent sexual exposure to HIV

Annals of Internal Medicine

Volumn 128, Issue 4, 1998, Pages 306-312

  Katz, Mitchell H ^a,b   Gerberding, Julie Louise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT ATTITUDE; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; TREATMENT PLANNING;

EID: 0032519847     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-4-199802150-00012     Document Type: Review

References (77)

1. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large U.S. metropolitan areas. Am J Public Health. 1996;86:642-54.
2. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 1995;44:929-33.
3. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV-infected blood: clinical and public health implications. N Engl J Med. 1997;337:1485-90.
4. Voelker R. New HIV drugs cast in supporting roles. JAMA. 1996;276:585.
5. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996;276:146-54.
6. Gerberding JL. Prophylaxis for occupational exposure to HIV. Ann Intern Med. 1996;125:497-501.
7. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med. 1997;336:1097-100.
8. Makadon HJ, Silin JG. Prevention of HIV infection in primary care: current practices, future possibilities. Ann Intern Med. 1995;123:715-9.
9. Hearst N. AIDS risk assessment in primary care. J Am Board Fam Pract. 1994;7:44-8.
10. Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wolinsky SM, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996;183:215-25.
11. Pinto LA, Landay AL, Berzofsky JA, Kassler HA, Shearer GM. Immune response to human immunodeficiency virus (HIV) in health care workers occupationally exposed to HIV-contaminated blood. Am J Med. 1997;102(Suppl 5B):21-4.
12. Blauvelt A, Katz SI. The skin as target, vector, and target effector organ in human immunodeficiency disease. J Invest Dermatol. 1995;105(Suppl):122S-6S.
13. DeGruttola V, Seage GR 3d, Mayer KH, Horsburgh CR Jr. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol. 1989; 42:849-56.
14. Wiley JA, Herschkorn SJ, Padian NS. Heterogeneity in the probability of HIV transmission per sexual contact: the case of male-to-female transmission in penile-vaginal intercourse. Stat Med. 1989;8:93-102.
15. Peterman TA, Stoneburner RL, Allen JR, Jaffe HW, Curran JW. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA. 1988;259:55-8.
16. Downs AM, De Vincenzi I. Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:388-95.
17. Lifson AR, O'Malley PM, Hessol NA, Buchbinder SP, Cannon L, Rutherford GW. HIV seroconversion in two homosexual men after receptive oral intercourse with ejaculation: implications for counseling concerning safe sexual practices. Am J Public Health. 1990;80:1509-11.
18. Samuel MC, Mohr MS, Speed TP, Winkelstein W. Infectivity of HIV by anal and oral intercourse among homosexual men. In: Kaplan EH, Brandeau ML, eds. Modeling the AIDS Epidemic: Planning, Policy, and Prediction. New York: Raven; 1994:423-38.
19. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257-64.
20. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med. 1997;336:1072-8.
21. Berrios DG, Hearst N, Coates TJ, Stall R. Hudes ES, Turner H, et al. HIV antibody testing among those at risk for infection. The National AIDS Behavioral Surveys. JAMA. 1993;270:1576-80.
22. Wortley PM, Chu SY, Diaz T, Ward JW, Doyle B, Davidson AJ, et al. HIV testing patterns: where, why, and when were persons with AIDS tested for HIV? AIDS. 1995;9:487-92.
23. Horsburgh CR Jr, Ou CY, Jason J, Holmberg SD, Longini IM Jr, Schable C, et al. Duration of human immunodeficiency virus infection before detection of antibody. Lancet. 1989;2:637-40.
24. Spielberg F, Kassler WJ. Rapid testing for HIV antibody: a technology whose time has come [Editorial]. Ann Intern Med. 1996;125:509-11.
25. Irwin K, Olivo N, Schable CA, Weber JT, Janssen R, Ernst J. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. Ann Intern Med. 1996;125:471-5.
26. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA. 1997;277:1962-9.
27. Liuzzi G, Chirianni A, Clementi M, Bagnarelli P, Valenza A, Cataldo PT, et al. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS. 1996; 10:F51-6.
28. Rasheed S, Li Z, Xu D, Kovacs A. Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women. Am J Obstet Gynecol. 1996;175:122-9.
29. Mayers DL. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am J Med. 1997;102(Suppl 5B):70-5.
30. Albert J, Wahlberg J, Leitner T, Escanilla D, Uhlen M. Analysis of a rape case by direct sequencing of the human immunodeficiency virus type 1 pol and gag genes. J Virol. 1994;68:5918-24.
31. Claydon E, Murphy S, Osborne EM, Kitchen V, Smith JR, Harris JR. Rape and HIV. Int J STD AIDS. 1991;2:200-1.
32. Gostin LO, Lazzarini Z, Alexander D, Brandt AM, Mayer KH, Silverman DC. HIV testing, counseling, and prophylaxis after sexual assault. JAMA. 1994;271:1436-44.
33. 1998 STD treatment guidelines. MMWR Morb Mortal Wkly Rep. [In press].
34. Thompson JL, Yager TJ, Martin JL. Estimated condom failure and frequency of condom use among gay men. Am J Public Health. 1993;83:1409-13.
35. Messiah A, Dart T, Spenser BE, Warszawski J. Condom breakage and slippage during heterosexual intercourse: a French national survey. French National Survey on Sexual Behavior Group (ACSF). Am J Public Health. 1997; 87:421-4.
36. Update: provisional Public Health Service recommendation for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep. 1996;45:468-80.
37. Public Health Service (PHS) statement on management of occupational exposures to HIV and recommendations for chemoprophylaxis after exposure. MMWR Morb Mortal Wkly Rep. [In press].
38. Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119-25.
39. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997;277:145-53.
40. Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993;328:1163-5.
41. Rubio A, Leal M, Pineda JA, Caruz A, Luque F, Rey C, et al. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996 [Letter]. AIDS. 1997;11:1184-6.
42. St. Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King CL, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991;253:1557-9.
43. Conway B, Montessori V, Rouleau D, Montawer JS, Frawsew S, Shillington A, et al. Primary lamivudine resistance in acute HIV infection [Abstract], Proceedings from the International Workshop on HIV Drug Resistance Treatment Strategies and Eradication. St. Petersburg, Florida, 25-28 June 1997.
44. Trussell J, Ellertson C. Efficacy of emergency contraception. Fertility Control Reviews. 1995;4:8-11.
45. 1993 sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep. 1993;42(RR-14):97-102.
46. Buchbinder SP, Douglas JM Jr, McKirnan DJ, Judson FN, Katz MH, MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis. 1996;174:954-61.
47. Chmiel JS, Detels R, Kaslow RA, van Raden M, Kingsley LA, Brookmeyer R. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol. 1987; 126:568-77.
48. Eng TR, Butler WT, eds. The Hidden Epidemic: Confronting Sexually Transmitted Disease. Washington, DC: National Academy Pr; 1996.
49. Update: recommendations to prevent hepatitis B virus transmission - United States. MMWR Morb Mortal Wkly Rep. 1995;44:574-5.
50. Manley M, Epps RP, Husten C, Glynn T, Shopland D. Clinical intervention in tobacco control. A National Cancer Institute training program for physicians. JAMA. 1991;266:3172-3.
51. Fleming MF, Barry KL, Manwell LB, Johnson K, London R. Brief physician advice for problem alcohol drinkers. A randomized controlled trial in community-based primary care practices. JAMA. 1997;277:1039-45.
52. Technical guidance on HIV counseling. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 1993;42(RR-2):11-7.
53. American Medical Association. A Physician Guide to HIV Prevention. Chicago: American Medical Assoc; 1996.
54. Chesney MA, Lurie P, Coates TJ. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:30-5.
55. Kamb ML, Peterman T, Fishbein M, Grazlano S, Bolan G, Zenilman J, et al. Does HIV/STD prevention counseling work? Project Respect [Abstract]. Proceedings from the 1996 National STD Prevention Conference. Tampa, Florida, 9-12 December 1996.
56. DiClemente RJ, Wingood GM. A randomized controlled trial of an HIV sexual risk-reduction intervention for young African-American women. JAMA. 1995;274:1271-6.
57. Peterson JL, Coates TJ, Catania J, Hauck WW, Acree M, Daigle D, et al. Evaluation of an HIV risk reduction intervention among African-American homosexual and bisexual men. AIDS. 1996;10:319-25.
58. Janz NK, Zimmerman MA, Wren PA, Israel BA, Freudenberg N, Carter RJ. Evaluation of 37 AIDS prevention projects: successful approaches and barriers to program effectiveness. Health Educ Q. 1996;23:80-97.
59. Choi K-H, Coates TJ. Prevention of HIV infection [Editorial]. AIDS. 1994;8: 1371-89.
60. Kelly JA, Murphy DA, Sikkema KJ, Kalichman SC. Psychological interventions to prevent HIV infection are urgently needed. New priorities for behavioral research in the second decade of AIDS. Am Psychol. 1993;48:1023-34.
61. Kelly JA, Murphy DA, Washington CD, Wilson TS, Koob JJ, Davis DR, et al. The effects of HIV/AIDS intervention groups for high-risk women in urban clinics. Am J Public Health. 1994;84:1918-22.
62. Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274:1226-31.
63. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med. 1991;324:954-60.
64. Ho DD. Time to hit HIV, early and hard [Editorial]. N Engl J Med. 1995;333: 450-1.
65. Kinloch-De Loes S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995;333:408-13.
66. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324:961-4.
67. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr Hum Retrovirol. 1994;7:1169-84.
68. Cates W Jr, Cohen MS. Early treatment of HIV infection [Letter]. N Engl J Med. 1995;333:1783.
69. Vernazza PL, Gilliam BL, Dyer J, Fiscus SA, Eron JJ, Frank AC, et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS. 1997;11:987-93.
70. Feder HM Jr, Milch LR. Viral load and combination therapy for human immunodeficiency virus [Letter]. N Engl J Med. 1997;336:959-60.
71. Li RW, Wong JB. Postexposure treatment of HIV [Letter]. N Engl J Med. 1997;337:499-500.
72. Pinkerton SD, Holtgrave DR, Bloom FR. Postexposure treatment of HIV [Letter]. N Engl J Med. 1997;337:500-1.
73. Pinkerton SD, Holtgrave DR, Pinkerton HJ. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med 1997;157: 1972-80.
74. Fleishman JA, Mor V. Insurance status among people with AIDS: relationships with sociodemographic characteristics and service use. Inquiry. 1993;30:180-8.
75. Diaz T, Chu SY, Conti L, Nahlen BL, Whyte B, Mokotoff E, et al. Health insurance coverage among persons with AIDS: results from a multistate surveillance project. Am J Public Health. 1994;84:1015-18.
76. Stall R, Ekstrand M, Pollack L, McKusick L, Coates TJ. Relapse from safer sex: the next challenge for AIDS prevention efforts. J Acquir Immune Defic Syndr. 1990;3:1181-7.
77. McCusker J, Stoddard AM, McDonald M, Zapka JG, Mayer KH. Maintenance of behavioral change in a cohort of homosexually active men. AIDS. 1992;6:861-8.